Latham & Watkins Advises Mineralys Therapeutics in US$120 Million Private Placement Financing

Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease, and other diseases driven by abnormally elevated aldosterone, has announced that it has entered into a securities purchase agreement with institutional accredited investors to sell securities in a private placement financing (the PIPE) for gross proceeds of approximately US$120 million, before deducting estimated fees and expenses.

Latham & Watkins LLP is advising Mineralys in the PIPE with a corporate team led by San Diego partners Cheston Larson and Matt Bush, and counsel Anthony Gostanian, with associates Derek Rogers and Samantha Wang.